Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients

ClinicalTrials.gov ID: NCT00728936

Public ClinicalTrials.gov record NCT00728936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Multi-center, Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients Unresponsive to Standard Treatment With Pegylated Interferon and Ribavirin

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.

Study identification

NCT ID
NCT00728936
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Enrollment
58 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2007
Primary completion
Nov 30, 2009
Completion
Apr 30, 2010
Last update posted
Feb 14, 2019

2007 – 2010

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
6
Facility City State ZIP Site status
University of Colorado Hospital Aurora Colorado 80045
Gastoenterstinal Specialist of Georgia, PA Marietta Georgia 30060
Henry Ford Med Ctr- Columbus Novi Michigan 48377
Duke University Medical Center Durham North Carolina 27705
The Liver Institute Dallas Texas 75203
Alamo Medical Research San Antonio Texas 78215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00728936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 14, 2019 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00728936 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →